Physician profile
Paul Wang
NPI 1780386383
$630.84
in general payments reported to CMS, 2019-2025
14 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $31.23 · 2024: $247 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $140.49 | 2025 | Uplizna |
| Ucb, INC. | $111.76 | 2024-2025 | Briviact, Rystiggo |
| Jazz Pharmaceuticals INC. | $77.87 | 2023-2024 | Epidiolex |
| Novartis Pharmaceuticals Corporation | $62.34 | 2024 | |
| Lilly USA, LLC | $44.67 | 2025 | Amyvid, Kisunla |
| Astrazeneca Pharmaceuticals LP | $37.95 | 2025 | Wainua |
| Tg Therapeutics, INC. | $33.28 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $22.11 | 2025 | Onpattro |
| Lundbeck LLC | $21.97 | 2025 | Vyepti |
| Merck Sharp & Dohme LLC | $18.93 | 2024 | Zerbaxa, Recarbrio |
| Genentech USA, INC. | $16.37 | 2025 | Ocrevus Zunovo |
| Pfizer INC. | $14.72 | 2024 | |
| Abbvie INC. | $14.70 | 2023 | |
| Tanabe Pharma America, INC. | $13.68 | 2025 | Radicava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.